EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toxicological Assessment of Origanum majorana L.: Evaluation of Its Cytotoxicity, Genotoxicity, and Acute Oral Toxicity

Ayfer Beceren iD, Ayse Nur Hazar-Yavuz iD, Ozlem Bingol Ozakpinar iD, Duygu Taskin iD, İsmail Senkardes iD, Turgut Taskin iD, Ozlem Tugce Cilingir-Kaya iD, Ahmad Kado iD, Hatice Kubra Elcioglu iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ayfer Beceren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye. Hauptthemen laut MEDLINE: Plant Extracts, Origanum. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marmara University Support Program for Research Universities (ADEP), Marmara University ADEP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medicinal plants remain central to traditional healthcare, yet their increasing integration into modern pharmacology necessitates robust toxicological evaluation. Origanum majorana L. (sweet marjoram), widely used in culinary and folk medicine, contains diverse secondary metabolites with both therapeutic and potential genotoxic activities. Despite its popularity, systematic in vivo and in vitro safety assessments remain limited. This study aimed to comprehensively evaluate the acute oral toxicity, cytotoxicity, and genotoxicity of O. majorana methanolic extract, providing baseline toxicological data to support its safe traditional use and potential pharmaceutical applications. The methanol extract of O. majorana leaves was tested in NIH-3T3 fibroblasts for cytotoxicity and genotoxicity. In vivo acute oral toxicity was assessed in rats according to OECD Guideline 420, with animals monitored over 14 days for clinical signs, hematological and biochemical alterations, and histopathological changes. The extract preserved fibroblast viability above 90% across all tested concentrations (10–200 µg/mL), indicating absence of cytotoxicity. However, comet and micronucleus assays revealed dose-dependent DNA damage, suggesting genotoxic potential at higher exposures. In vivo, no mortality or overt systemic toxicity was observed at doses up to 2000 mg/kg. Hematological analyses showed immunomodulatory shifts (increased neutrophils and monocytes, reduced eosinophils), while biochemical profiles indicated hepatoprotective and cardioprotective effects, with reduced ALT, AST, and LDH levels. Histopathological evaluation revealed only mild, focal changes consistent with adaptive rather than irreversible responses. O. majorana extract demonstrates a favorable acute safety profile with preserved hepatic and renal function, hematological modulation, and absence of in vitro cytotoxicity. Nevertheless, dose-dependent genotoxicity warrants caution for concentrated formulations. According to GHS classification, the extract aligns with Category 5 (acute oral toxicity, lowest hazard) and Category 2 (germ cell mutagenicity). These findings underscore the importance of dose management and further long-term genotoxicity studies before translational applications in nutraceutical or biomedical fields.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plant ExtractsOriganumAnimalsMiceRatsMaleDNA DamageNIH 3T3 CellsAdministration, OralToxicity Tests, AcuteMicronucleus TestsCell SurvivalPlant LeavesFemaleMutagenicity Tests

Stichwörter der Autor:innen

Origanum majorana L.acute toxicitybiochemical analysishaematological analysishistological analysis

Substanzen

Plant Extracts

Autor:innen und Institutionen

  • Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye.
  • Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye.
  • Department of Biochemistry, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye.
  • Marmara Pharmacy Drug and Innovative Product Development Unit, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye.
  • Department of Analytical Chemistry, Faculty of Pharmacy, University of Health Sciences, Istanbul 34668, Türkiye.
  • Department of Pharmaceutical Botany, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye.

ORCID-Profile: Ayfer Beceren, Ayse Nur Hazar-Yavuz, Ozlem Bingol Ozakpinar, Duygu Taskin, İsmail Senkardes, Turgut Taskin, Ozlem Tugce Cilingir-Kaya, Ahmad Kado, Hatice Kubra Elcioglu

Förderung

  • Marmara University Support Program for Research Universities (ADEP)
  • Marmara University ADEP

Zitieren

APA

Beceren, A., Hazar-Yavuz, A. N., Bingol Ozakpinar, O., Taskin, D., Senkardes, İ., Taskin, T., Cilingir-Kaya, O. T., Kado, A., & Elcioglu, H. K. (2025). Toxicological Assessment of Origanum majorana L.: Evaluation of Its Cytotoxicity, Genotoxicity, and Acute Oral Toxicity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199461

Vancouver

Beceren A, Hazar-Yavuz AN, Bingol Ozakpinar O, Taskin D, Senkardes İ, Taskin T, et al. Toxicological Assessment of Origanum majorana L.: Evaluation of Its Cytotoxicity, Genotoxicity, and Acute Oral Toxicity. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199461

BibTeX
@article{Beceren2025,
  author = {Beceren, Ayfer and Hazar-Yavuz, Ayse Nur and Bingol Ozakpinar, Ozlem and Taskin, Duygu and Senkardes, İsmail and Taskin, Turgut and Cilingir-Kaya, Ozlem Tugce and Kado, Ahmad and Elcioglu, Hatice Kubra},
  title = {Toxicological Assessment of Origanum majorana L.: Evaluation of Its Cytotoxicity, Genotoxicity, and Acute Oral Toxicity},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199461}
}
Kostenlos starten →